Purchase this article with an account.
George Dimitris Pappas; Aflibercept for AMD patients treated unsuccessfully with Ranibizumab and Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1505.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the Aflibercept efficacy in AMD patients where Ranibizumab and Bevacizumab failed to treat them successfully.
24 AMD patients, previously unsuccessfully treated with Ranibizumab and Bevacizumab assigned for treatment with Aflibercept. The mean number of previous injections was 9 of both agents in order to avoid tachyphylaxis. Visual Acuity, Central Macular Thickness (CMT) and side effects were evaluated. The mean CMT prior to Aflibercept introduction was 384μm (SD 55.10). The follow up period was 6 months
Mean reductin in CMT was 50.8μm (p<0.01). 16 of the 24 patients improved VA by a mean of 3 letters. For the 16 patients with the increased VA the mean CMT reduction was 84.4μ ( p<0.001).
We believe that Aflibercept is a potent agent and can improve VA in patients where other anti-VEGF agents fail to achieve it.
This PDF is available to Subscribers Only